Thirty-Day Post-Discharge Outcomes Following COVID-19 Infection

Abstract

Background

The clinical course of COVID-19 includes multiple disease phases. Data describing post-hospital discharge outcomes may provide insight into disease course. Studies describing post-hospitalization outcomes of adults following COVID-19 infection are limited to electronic medical record review, which may underestimate the incidence of outcomes.

Objective

To determine 30-day post-hospitalization outcomes following COVID-19 infection.

Design

Retrospective cohort study

Setting

Quaternary referral hospital and community hospital in New York City.

Participants

COVID-19 infected patients discharged alive from the emergency department (ED) or hospital between March 3 and May 15, 2020.

Measurement

Outcomes included return to an ED, re-hospitalization, and mortality within 30 days of hospital discharge.

Results

Thirty-day follow-up data were successfully collected on 94.6% of eligible patients. Among 1344 patients, 16.5% returned to an ED, 9.8% were re-hospitalized, and 2.4% died. Among patients who returned to the ED, 50.0% (108/216) went to a different hospital from the hospital of the index presentation, and 61.1% (132/216) of those who returned were re-hospitalized. In Cox models adjusted for variables selected using the lasso method, age (HR 1.01 per year [95% CI 1.00–1.02]), diabetes (1.54 [1.06–2.23]), and the need for inpatient dialysis (3.78 [2.23–6.43]) during the index presentation were independently associated with a higher re-hospitalization rate. Older age (HR 1.08 [1.05–1.11]) and Asian race (2.89 [1.27–6.61]) were significantly associated with mortality.

Conclusions

Among patients discharged alive following their index presentation for COVID-19, risk for returning to a hospital within 30 days of discharge was substantial. These patients merit close post-discharge follow-up to optimize outcomes.

Supplementary Information

The online version contains supplementary material available at 10.1007/s11606-021-06924-0.

INTRODUCTION

The burden of the novel coronavirus disease (COVID-19) is increasing with more than 70 million cases and 1.6 million deaths as of November 2020,¹ with a cost of nearly $17 trillion in the USA alone in 2020.² While many studies have examined in-hospital outcomes,^3–5 the consequences of COVID-19 likely extend beyond the hospitalization period.^6–8 Similar to other conditions,^19–11 it is likely that the first 30 days following hospital discharge are an especially vulnerable period for adverse outcomes. Yet, few studies to date have focused on post-hospitalization outcomes in COVID-19; and among these studies, only post-hospitalization outcomes obtained by electronic medical record system abstraction have been captured, raising concern for underestimation of adverse outcomes.^12–20 Therefore, the actual incidence of COVID-associated post-discharge return to the emergency room, re-hospitalization, and mortality remains unknown.

To address this important gap in knowledge, we conducted a retrospective study of 30-day post-discharge outcomes among adults discharged alive from our hospital system in New York City following a symptomatic confirmed COVID-19 infection. The objectives of this study were to determine the incidence of return to an emergency room, re-hospitalization, and mortality in the first 30 days after discharge from the ED or hospital, and to identify determinants of these outcomes.

METHODS

Study Design

This was a retrospective observational cohort study of adults from a COVID-19 clinical registry.²¹

Study Population

We examined consecutive adults aged at least 18 years who presented with acute COVID-19 to either New York-Presbyterian/Weill Cornell Medical Center (NYP/WCMC) or Lower Manhattan Hospital (NYP/LMH) in New York City between March 3 (date of the first case) and May 15, 2020 (which was the peak of the first wave of the COVID-19 pandemic in the region); and were subsequently discharged alive from either the ED or following a hospitalization. As has been previously described,²¹ cases were confirmed to have COVID-19 through reverse-transcriptase-polymerase-chain-reaction (RT-PCR) assays performed on nasopharyngeal specimens. We included the index presentation for each patient. Patients discharged to hospice services were excluded.

Study Setting

NYP/WCMC is an 862-bed quaternary referral center located in the Upper East Side of Manhattan, New York; and NYP/LMH is an affiliated 180-bed community hospital located in the Lower East Side of Manhattan, NY.

Data Collection

Study procedures for this cohort have been previously described.²¹ Briefly, chart abstraction was conducted by trained personnel who recorded parameters related to demographics, medical history, symptoms, imaging and laboratory values, in-hospital complications, in-hospital treatment, and length of stay. Data were entered into a RedCap database.²² Prior evaluation of inter-abstractor agreement was high (r=0.92).

Outcomes

The main study outcomes were as follows: 1) return to any ED, 2) re-hospitalization, and 3) death within 30 days of discharge. To collect these data, we contacted patients by phone at least 30 days after the discharge date. Specifically, we called patients up to six times at different times of the day, over a 2-week period. For patients who did not answer our attempted calls, we contacted the listed healthcare proxy to ascertain whether the patient had experienced any outcome of interest. If an event occurred, we inquired about the event date. Patients were considered lost-to-follow-up if we were unable to ascertain data from either the patient or their healthcare proxy after these attempts.

Statistical Analysis

We calculated medians with interquartile ranges for continuous variables and proportions for categorical variables. To identify independent determinants of each outcome, we created separate models for each of the three outcomes using the following multi-step procedure. First, we used the statistical method Lasso to generate a sequence of models which best fit the data.²³ Lasso finds the best models for the data with a given sum of absolute values of the regression coefficients. By forcing the overall size of the coefficients to be small through regularization, this method zeroes out coefficients for less important variables, and thus selects a subset of variables considered important for the model. We then chose the model which best satisfied the assumptions among the models nearby the model given by the one-standard-error rule for tuning parameter selection. Variables from these models were then inputted into a multivariable Cox proportional hazard model (without regularization).

Variables under consideration for selection included socio-demographics (age, sex, race, housing status), length of stay, comorbidities (tobacco use, body mass index [BMI], cardiovascular disease, chronic kidney disease, diabetes, chronic lung disease, HIV, active cancer, and other immunocompromised state), symptoms (fever, cough, diarrhea, nausea/vomiting, myalgia, dyspnea), and chest imaging at presentation; clinical course (new-onset myocardial infarction/arrhythmia/heart failure, dialysis, vasopressor requirement, hypoxia upon presentation, intubation/extubation, and tracheostomy) and infection parameters (PCR viral load, respiratory viral pathogen panel, and blood culture). Of note, separate analyses including either length of stay, days from symptom onset to admission, or days from symptom onset to discharge were performed and yielded similar results. Therefore, we included the conventional variable, length of stay, in this analysis. PCR viral load was based on cycle threshold (Ct) value, which represents the number of replication cycles required for sufficient gene amplification to produce a fluorescent signal that crosses a predefined threshold. Based on prior work that defined viral load according to terciles and demonstrated a dose-response relationship with mortality, low, medium, and high viral loads were defined as PCR cycle threshold >30, 25–30, and <25 cycles, respectively.²⁴

We used multivariate imputation by chained equations (MICE) to account for missing data.^{25, 26} Missingness was highest for race (13% missing) and BMI (7% missing); the remaining variables had <1% missing. All models were tested to ensure none of the variables violated the proportional hazard assumptions using Schoenfeld residuals. The low mortality rate in this cohort precluded the need to consider death as a competing risk. To determine statistical significance, we used 2-sided hypothesis testing with a p-value <0.05. These analyses were performed using R version 3.5.1 software (R Foundation, Vienna, Austria).

Ethical Considerations

This study was approved by the institutional review board of Weill Cornell Medicine (IRB: 20-03021681) and granted a waiver of informed consent.

RESULTS

Study Population

Between March 3 and May 15, 2020, 1935 patients presented to either WCMC or LMH (Fig. 1). As of June 15, 2020, 287 (14.8%) died during the index hospitalization, 183 (9.5%) remained hospitalized, 8 (0.4%) were discharged to hospice care, and 36 (1.9%) were transferred to outside hospitals for which we did not have access to medical records. Among the 1421 patients eligible for this study, we collected 30-day follow-up data on 1344 patients (94.6% of eligible patients).

Figure 1.

Exclusion cascade describing COVID-19-infected patients included in the analysis.

Characteristics of the Study Population

The baseline characteristics of this cohort are shown in Table 1. The median age was 61.0 years (IQR 48–72), and 44.5% were female. Common comorbid conditions were hypertension (51.2%), diabetes (28.3%), and chronic kidney disease (9.1%). The majority of patients presented with fever (71.4%), cough (72.1%), or dyspnea (61.2%). Of those who received a respiratory viral panel PCR swab, 1.9% (6/312) were positive for a viral co-infection. Initial chest radiograph revealed bilateral pulmonary infiltrates in 60.1% of patients.

Table 1.

Baseline Characteristics of Cohort

Study participants (n=1344)	Variable n (%) Mean (SD)
Patient demographics
Age (years)	61.0 (48−72)
Female	598 (44.5%)
Race	27.6 (5.9)
Asian	211 (15.7%)
Black	202 (15.0%)
White	454 (33.8%)
Other	301 (22.4%)
Decline to answer	176 (13.1%)
Body mass index (kg/m2)	27 (24−32)
Healthcare worker	120 (8.9%)
Admitted from:
Home	1206 (89.7%)
Nursing/Rehab Facility	65 (4.8%)
Undomiciled	24 (1.8%)
Health behaviors/comorbidities
Past medical history
Diabetes	381 (28.3%)
Hypertension	688 (51.2%)
COPD	52 (3.9%)
Chronic kidney disease	47 (3.5%)
ESRD	75 (5.6%)
Cirrhosis	16 (1.2%)
Coronary artery disease	159 (11.8%)
Heart failure	72 (5.4%)
Cancer	71 (5.3%)
HIV	27 (2.0%)
Immunosuppression	24 (1.8%)
Current tobacco/vape use	236 (17.6%)
Presenting symptoms/hospital course
Dyspnea	822 (61.2%)
Fever	960 (71.4%)
Cough	969 (72.1%)
Diarrhea	361 (26.9%)
Nausea or vomiting	274 (20.4%)
Myalgias	315 (23.4%)
Supplemental O2 within first 3 h
No oxygen required	817 (60.8%)
Nasal cannula	400 (29.9%)
Noninvasive/BiPAP	106 (7.9%)
Mechanical ventilation	21 (1.6%)
Initial chest radiograph
Normal	364 (27.1%)
Unilateral infiltrates	172 (12.8%)
Bilateral infiltrates	808 (60.1%)
Positive respiratory viral panel*	6 (0.4%)
Positive blood culture	42 (3.1%)
During hospitalization:
Myocardial infarction	24 (1.8%)
New arrhythmia	50 (3.7%)
New heart failure	25 (1.9%)
Dialysis requirement	61 (4.5%)
Required intubation	138 (10.3%)
Extubated or tracheostomy	20 (1.5%)
Discharged from ED	201 (15.0%)
Days from symptom onset to admission	7 (3−10)
Days from symptom onset to discharge	14 (7−21)
Length of hospital stay (if admitted)	6 (3−12)

COPD, chronic obstructive pulmonary disease; ESRD, end-stage renal disease; BiPAP, bilevel positive airway pressure

*Positive for viral pathogen in addition to COVID-19

Characteristics stratified by whether the patient was discharged alive from the ED or following hospitalization are shown in Supplemental Table 1. Among patients discharged alive from the ED (15.0%, 201/1344), the median age was 49 years (IQR 48–72), 48.3% were male, and the median BMI was 28 kg/m² (IQR 24–32). Most presented from home (90.5%), and 24.9% were healthcare workers. The most common comorbid conditions were hypertension (34.8%), diabetes (16.4%), and coronary artery disease (7.5%). Six patients (3.0%) required supplemental oxygen by nasal cannula. Fever (73.1%), cough (71.1%), and dyspnea (51.2%) were the most common presenting symptoms. Bilateral infiltrates on chest radiograph were present in 20.4%.

Among the patients discharged alive following hospitalization (85.0%, 1143/1344), median age was 63.0 years (IQR 50–73), 43% were female, and the median BMI was 27kg/m² (IQR 24–32). The most common comorbid conditions were hypertension (54%), diabetes (30.4%), and coronary artery disease (12.6%). On admission, fever (71.1%), cough (72.3%), and dyspnea (62.9%) were the most common presenting symptoms. Nearly half (45.4%) required supplemental oxygen within the first 3 h of presentation—34.5% required nasal cannula, 9.1% required noninvasive ventilation, and 1.8% required mechanical ventilation. During the hospital stay, 12.1% were intubated at a median of 1.5 days (IQR 1.00–3.75) after admission, and 12% required vasopressors. Arrhythmia (4.4%), heart failure (2.2%), and myocardial infarction (2.1%) occurred infrequently.

Outcomes

Among the full cohort of 1344 patients, 16.5% (216/1,344) returned to an ED, 9.8% (132/1344) were re-hospitalized, and 2.4% (32/1344) died within 30 days of discharge. Kaplan-Meier analysis is shown in Figure 2. The median time from discharge to return to an ED was 6.2 days (IQR 2.3–16.8), median time to re-hospitalization was 5.4 days (IQR 1.9–13.5), and median time to death was 9.3 days (IQR 5.4–14.5). Fifty percent of patients (108/216) who returned to the emergency room went to a different hospital from that of the index presentation.

Figure 2.

Kaplan-Meier curve depicting 30-day post-discharge return the emergency room, re-hospitalization, and mortality of cohort patients.

Among patients who returned to the ED, 61.1% (132/216) were re-hospitalized. Among patients who returned to the ED but were not hospitalized, the mortality rate was 1.5%; and among patients who were hospitalized, the mortality rate was 2.5%. Among patients who died, nearly half (46.9%) died without re-presenting to the hospital.

Of note, patients discharged after hospitalization were more likely to return to the ED (23.4 vs. 14.8%, p=0.002) and numerically more likely to be re-hospitalized (12.4% vs. 9.4%, p=0.18) compared to those discharged from the ED. Mortality rates were similar in these groups (1.5% vs. 2.5%, p=0.37).

Factors Associated with Return to the Emergency Room

The Lasso model selected the following variables as important for return to the ED: age, sex, undomiciled status, need for dialysis, bilateral infiltrates on presenting chest radiograph, and discharge following hospitalization. Based on a univariate Cox proportional hazard model, age, sex, undomiciled status, and need for dialysis were associated with return to the emergency room; and bilateral infiltrates and discharge from inpatient hospitalization were inversely associated with return to the emergency room. (Supplemental Table 2).

In a multivariable Cox proportional hazard regression analysis, older age (HR 1.007 per year [95% CI 1.00–1.02]), undomiciled status (5.13 [2.83–9.30]), and need for dialysis during index hospitalization (3.59 [2.29–5.65]) were significantly associated with returning to the ED within 30 days of discharge; and bilateral chest radiograph infiltrate on presenting chest radiograph (0.46 [0.33–0.63]) was inversely associated with returning to the ED within 30 days of discharge (Table 2). In a sensitivity analysis including a subset of 970 patients with available COVID-19 PCR cycle threshold, the multivariable Cox proportional hazard regression analysis revealed similar results (Supplemental Table 3). Additionally, high cycle threshold (i.e., low viral load) was associated with a trend toward higher risk of return to the emergency room (1.36 [0.95–1.95]).

Table 2.

Multivariable Cox Proportional Hazard Regression Analysis for Return to an Emergency Room, Re-hospitalization, and Mortality Within 30 Days of Index Hospital Discharge

Variable	HR (CI)	p-value*
Return to an emergency room
Age (years)	1.01 (1.00−1.02)	0.070
Sex
Male	Ref	--
Female	1.28 (0.97−1.68)	0.086
Race
White	Ref	--
Asian	1.15 (0.77−1.72)	0.494
Black	1.01 (0.68−1.50)	0.954
Other	0.95 (0.65−1.38)	0.777
Undomiciled	5.13 (2.83−9.3)	<0.0001
Dialysis required	3.59 (2.29−5.65)	<0.0001
Hospitalized vs ED discharge	0.73 (0.51−1.05)	0.091
Infiltrates on initial chest radiograph
None	Ref	--
Unilateral	0.75 (0.49−1.13)	0.162
Bilateral	0.46 (0.33−0.63)	<0.0001
Re-hospitalization
Age (years)	1.01 (1.00−1.02)	0.021
Sex
Male	Ref	--
Female	1.11 (0.78−1.58)	0.563
Race
White	Ref	--
Asian	1.12 (0.68−1.84)	0.645
Black	1.02 (0.61−1.70)	0.934
Other	0.84 (0.51−1.36)	0.471
History of diabetes	1.54 (1.06−2.23)	0.023
Dyspnea on arrival	0.63 (0.44−0.91)	0.013
Dialysis required	3.78 (2.23−6.43)	<0.0001
Hospitalized vs ED discharge	0.69 (0.44−0.91)	0.013
Infiltrates on initial chest radiograph
None	Ref	--
Unilateral	1.00 (0.59−1.68)	0.991
Bilateral	0.57 (0.37−0.88)	0.012
Mortality
Age (years)	1.08 (1.05−1.11)	<0.0001
Sex
Male	Ref	--
Female	1.70 (0.81−3.59)	0.200
Race
White	Ref	--
Asian	2.89 (1.27−6.61)	0.012
Black	0.31 (0.04−2.45)	0.300
Other	0.99 (0.34−2.89)	0.999

*p<0.05 in bold

Factors Associated with Re-hospitalization

The Lasso model selected the following variables as important for rehospitalization: age, diabetes, need for dialysis, dyspnea, and bilateral infiltrates on presenting chest radiograph. Based on a univariate Cox proportional hazard model, age, diabetes, and dialysis requirement were associated with re-hospitalization; and dyspnea and bilateral infiltrates were inversely associated with re-hospitalization (Supplemental Table 4).

In a multivariable Cox proportional hazard regression analysis, older age (HR 1.01 per year [95% CI 1.00–1.02]), diabetes (HR 1.54 [1.06–2.23]), and the need for dialysis (HR 3.78 [2.23–6.43]) during index presentation were statistically significantly associated with rehospitalization within 30 days of hospital discharge; and dyspnea (0.63 [0.44–0.91]) and bilateral infiltrates on presenting chest radiograph (0.57 [0.37–0.88]) remained inversely associated with rehospitalization within 30 days of discharge. In a sensitivity analysis including a subset of 970 patients with available COVID-19 PCR cycle threshold, the multivariable Cox proportional hazard regression analysis revealed similar results (Supplemental Table 5).

Factors Associated with Mortality

Based on a univariate Cox proportional hazard model, older age (1.09 [1.06–1.12]), Asian race (2.68 [1.17–6.14]), hypertension (HR 3.46 [1.49–7.99]), diabetes (1.98 [0.99–3.99]), chronic kidney disease (2.93 [0.89–9.66]), and active malignancy (3.40 [1.31–8.82]) were significantly associated with death within 30 days of hospital discharge (Supplemental Table 6). Conversely, bilateral infiltrates on chest radiograph (0.25 [0.11–0.57]), higher body mass index (0.92 [0.86–0.98]), presenting symptoms of fever (0.51 [0.25–1.03]), nausea (0.26 [0.06–1.08]), myalgia (0.33 [0.10–1.10), and dyspnea (0.33 [0.16–0.68]) were inversely associated with mortality.

In a multivariable Cox proportional hazard regression analysis, older age (HR 1.08 per year [95% CI 1.05–1.11]) and Asian race (HR 2.89 [95% CI 1.27–6.61]) were statistically significantly associated with mortality within 30 days of hospital discharge.

DISCUSSION

There were several important findings related to post-hospitalization outcomes in this study of adults hospitalized with COVID-19 during the initial wave of the pandemic in NYC. We report that post-discharge return to an emergency department and re-hospitalization were common and identify determinants of adverse post-hospitalization outcomes, which may inform ongoing care of COVID-19 survivors.

Within 30 days of hospital discharge, nearly one in seven (16.1%) patients returned to the ED, one in ten (9.8%) were re-hospitalized, and 2.4% had died. To our knowledge, this is the most complete study to date of 30-day post-hospitalization outcomes among COVID-19 infected patients, given our 5% lost to follow-up rate and inclusion of post-hospitalization outcomes occurring both within and beyond our own health system. These data add to observations that symptoms of COVID-19 can persist for several weeks,¹² and support the notion that the consequences of COVID-19 continue beyond hospital discharge. As was shown recently in a study from the Veterans Affairs healthcare system, the risk for adverse events is highest in the first 7–10 days following discharge.¹² Our observations further demonstrate that risk persists beyond that early period and support the need for close follow-up after discharge. Moreover, our data show that risk is substantial whether the index event was an ED visit or a hospitalization. This supports the urgent need for protocols to assess patients after discharge (from either the ED or following hospitalization) for post-sequelae complications of COVID-19 and also provide necessary resources to optimize their care.

Importantly, our data also indicate that approximately one-half of patients who either returned to the ED or were re-hospitalized did so at a different hospital from the index presentation. Additionally, among patients who died, less than one-half (46.9%) had been re-hospitalized and 6.2% had returned to an ED but were not re-hospitalized. This likely explains the discrepancy observed between these data and a prior study reporting a 2-month readmission rate of just 9%, which was based on electronic medical record review and thus may have led to an underestimation of re-hospitalization.¹⁴ Although the consequences of patients with COVID-19 returning to a different hospital are not clear, these findings further illustrate ongoing challenges in the USA with regard to fragmented care which has previously been shown to negatively impact health outcomes.^{27, 28} Coupled with our finding that a substantial number of deaths occurred without return to the ED or a hospitalization, these data should additionally inform study design for future studies examining healthcare utilization and long-term COVID-19 sequelae.

Age and incident renal failure requiring dialysis were significantly associated with return to the ED and/or re-hospitalization in the multivariable models. This was not surprising as age is one of the most important risk factors for adverse post-hospitalization outcomes in myriad other conditions (i.e., heart failure, stroke, and diabetes)^29–32; and renal failure requiring dialysis may be suggestive of a complicated hospital course. Additionally, patients with diabetes were ~50% more likely to be re-hospitalized within 30 days of discharge. Patients with these high-risk features likely warrant greater attention during the post-discharge period. While prediction tools assessing inpatient outcomes have been developed,^{33, 34} our work suggests the possible utility of developing prediction tools that focus on post-hospitalization outcomes. Future study is also warranted to determine whether prioritizing such patients for follow-up in multidisciplinary COVID-19 post-discharge clinics may be a fruitful strategy.^{35, 36}

Our observation that dyspnea and bilateral infiltrates on chest radiograph were inversely associated with returning to the ED and re-hospitalization was unexpected. We speculate that one possible explanation for this finding is that a classic, easily identifiable presentation in the setting of a novel viral syndrome, which can present in multiple varied ways,^37–40 may have facilitated a more expedient diagnosis and perhaps more rapid treatment compared to those who presented in less typical ways. It is also possible that patients with more severe presentation (such as dyspnea and/or bilateral infiltrates on chest radiograph at presentation) received more aggressive treatment compared to those who did not have these features at presentation, which could have improved the outcomes among individuals who survived to discharge. Alternatively, it is possible that those presenting with classic symptoms have differing underlying pathophysiologic and/or immunologic mechanisms, therefore different outcomes. Future studies investigating these possibilities are needed.

There are important strengths and limitations to this study. To our knowledge, this is the first study of 30-day post-hospitalization outcomes of COVID-19 survivors based on patient contact—this minimized loss-to-follow-up and ensured accurate data including utilization of healthcare services outside of our healthcare system network. Another important strength is that these data were derived from a comprehensive COVID-19 registry which included chart-level data on all consecutive symptomatic patients who presented to one of two hospitals in NYC.²¹ There are also several limitations. First, these data were collected from a specific region—future studies are needed to better understand patterns of post-hospitalization outcomes in different areas of the country as clinical management may differ by region. Second, we did not have data on post-hospitalization processes such as the use of home health aides or whether patients had a follow-up ambulatory appointment—these aspects of care could have impacted outcomes. Finally, determinants of mortality should be interpreted with caution due to the relatively low number of events—future studies leveraging national cohorts will be necessary to better understand factors contributing to post-hospitalization mortality.

In conclusion, we report 30-day outcomes following hospital discharge after COVID-19 infection at two NYC hospitals, demonstrating that risk for adverse events from COVID-19 persists beyond the index presentation. COVID-19 infected adults merit close follow-up after discharge to fully optimize outcomes regardless of whether they are discharged from the emergency room or the hospital.

Funding

This study received support from the Weill Cornell Clinical and Translational Science Center (CTSC) (UL1 TR000457). Dr. Kingery is supported by the National Institutes of Health/National Heart Lung Blood Institute grant K23-HL-152926. Dr. Choi is supported by the National Institutes of Health/National Center for Advancing Translational Sciences grant KL2-TR-002385.

Declarations

Conflict of Interest

Dr. Safford has received research support from Amgen. Dr. Choi has received research support and consulting fees from Roche Diagnostics and Allergan unrelated to the work in this manuscript. Dr. Goyal has received personal fees for medicolegal consulting on heart failure.

The remaining authors have nothing to disclose.